Amgen (AMGN) Total Non-Current Liabilities (2009 - 2026)

Amgen has reported Total Non-Current Liabilities for 18 years, with the latest figure at $81.1 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 4.04% year-over-year to $81.1 billion in Q2 2026; TTM through Jun 2026 was $81.1 billion, a 4.04% increase from a year earlier, with the FY2025 full-year figure at $79.2 billion, down 5.23% from the prior year.
• Total Non-Current Liabilities was $81.1 billion for Q2 2026 at Amgen, up from $80.6 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $87.9 billion in Q1 2024, with the low at $51.3 billion in Q2 2022.
• Average Total Non-Current Liabilities over 5 years is $76.0 billion, with a median of $80.9 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities jumped 62.35% in 2023, then decreased 8.15% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $61.2 billion in 2022, then jumped by 40.94% to $86.2 billion in 2023, then retreated by 3.05% to $83.6 billion in 2024, then slipped by 5.23% to $79.2 billion in 2025, then gained by 2.36% to $81.1 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $81.1 billion (Q2 2026), $80.6 billion (Q1 2026), and $79.2 billion (Q4 2025), per Business Quant data.